Track topics on Twitter Track topics that are important to you
On 6 August, NICE issued draft guidance that does not recommend Rubraca for maintenance treatment of relapsed ovarian, fallopian tube or peritoneal cancer that has responded to platinum-based chemotherapy.
Original Article: NICE reject Clovis Oncology's ovarian cancer drug RubracaNEXT ARTICLE
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...